Here's the thing about drug trials: sometimes you can win on paper but lose where it counts. Agios Pharmaceuticals (AGIO) learned that lesson the hard way on Wednesday, watching its stock crater nearly 50% after releasing what looked like partially good news from its RISE UP Phase 3 trial testing mitapivat in sickle cell disease.

The Good, The Bad, and The Statistical Significance

The trial technically met its primary endpoint for hemoglobin response, and the numbers there were actually quite impressive. A full 40.6% of patients taking mitapivat achieved a hemoglobin response, compared to a mere 2.9% on placebo. That's statistically significant and genuinely meaningful for patients dealing with the chronic anemia that comes with sickle cell disease.

Mitapivat also nailed two other key secondary endpoints. The average change in hemoglobin concentration from Week 24 through Week 52 was 7.69 g/L in the mitapivat group versus just 0.26 g/L for placebo. Another win came with indirect bilirubin levels, a marker of hemolysis, or red blood cell destruction. The mitapivat arm saw levels drop by 16.03 µmol/L while placebo patients saw them rise by 0.88 µmol/L. Since elevated indirect bilirubin signals increased red blood cell destruction, which correlates with higher morbidity and mortality in sickle cell disease, this was meaningful progress.

But here's where things get tricky. The trial also measured annualized rates of sickle cell pain crises, which include acute pain requiring medical contact, acute chest syndrome, priapism, and hepatic or splenic sequestration. These crises are what make sickle cell disease so devastating for patients. Mitapivat showed 2.62 crises per year compared to 3.05 for placebo. That's a reduction, sure, but it didn't reach statistical significance. In the world of FDA approvals, that matters.

When Responders Respond

There's an interesting wrinkle buried in a post hoc analysis. Among the subset of mitapivat patients who actually achieved hemoglobin response, the drug showed clinically meaningful benefits in reducing both pain crises and hospitalizations for those crises. They also saw improvements in fatigue scores. The catch? That third key secondary endpoint measuring fatigue across all patients using the PROMIS Fatigue 13a score didn't meet its mark in the overall trial population.

The safety profile at least remained consistent with previous mitapivat trials in sickle cell disease, so no surprises there.

The Road Ahead

Despite the stock's brutal reaction, Agios isn't throwing in the towel. The company plans to meet with the FDA in the first quarter of 2026 for a pre-supplemental New Drug Application discussion, then submit a marketing application for mitapivat in sickle cell disease afterward.

More immediately, Agios is awaiting a potential U.S. approval for Pyrukynd, which is mitapivat's brand name, for thalassemia treatment. That decision should come in early December 2025. To position itself for that commercial launch while maintaining financial stability, the company announced it will reduce operating expenses and provide more details by early 2026.

As for the stock, it closed down 49% at $23.20 on Wednesday, hovering just above its 52-week low of $23.41. Investors clearly wanted more certainty that mitapivat could deliver on the pain crisis endpoint, the outcome that would make the biggest difference for patients' quality of life. Better hemoglobin levels matter, but not as much as fewer trips to the emergency room in excruciating pain.